CARSK

CARSK aims to test the hypothesis that after screening for wait list entry, no further screening for coronary artery disease (CAD) is non-inferior to the current standard care, which is screening all asymptomatic wait-listed patients for CAD at regular intervals, and to compare the benefits and costs of not screening versus regular CAD screening from a health system perspective. Time to first major adverse cardiac event (MACE) (cardiovascular death, myocardial infarction, emergency revascularization, hospitalization with unstable angina) and death -Time to MACE endpoint plus complications from cardiac diagnosis or treatment including major bleeding requiring transfusions or hospitalizations, vascular intervention subsequent to cardiac interventions stroke and all-cause death. -Time to death, cardiovascular death, procedure-related death, myocardial infarction, emergency revascularization, stroke, hospitalization with unstable angina, hospitalization with heart failure, hospitalization with arrhythmia, major bleeding, health-related quality of life (QoL), time off list (including number of temporary suspension and duration of each suspension), cost-effectiveness, incidence of permanent removal from list for cardiac causes; incidence of transplantation and cancellation of transplant due to CAD.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Medical Research
• Age: - 99 Years
• Gender: All